# Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients

> **NCT02850419** · PHASE2 · WITHDRAWN · sponsor: **Imunon**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** ThermoDox (Thermally Sensitive Liposomal Doxorubicin)
- **RADIATION:** Radiation Therapy
- **DEVICE:** Superficial Hyperthermia

## Key facts

- **NCT ID:** NCT02850419
- **Lead sponsor:** Imunon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-03
- **Primary completion:** 2019-12
- **Final completion:** 2020-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Administrative
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02850419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02850419, "Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02850419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*